News

Published on 23 Feb 2024 on Zacks via Yahoo Finance

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move...


Article preview image

Shares of Replimune Group, Inc. (REPL) have gained 0.8% over the past four weeks to close the last trading session at $7.95, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.56 indicates a potential upside of 70.6%.

The average comprises nine short-term price targets ranging from a low of $10 to a high of $19, with a standard deviation of $2.60. While the lowest estimate indicates an increase of 25.8% from the current price level, the most optimistic estimate points to a 139% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

NASDAQ.REPL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Tesla, Nvidia among Friday's market cap stock movers By Investing.com

Tesla, Nvidia among Friday's market cap stock movers

Investing.com 22 Nov 2024

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead...

Zacks · via Yahoo Finance 22 Nov 2024

Replimune's stock surges 19% after-hours on FDA BLA submission By Investing.com

Shares of Replimune Group Inc (NASDAQ:REPL) surged more than 19% in after-hours trading following...

Investing.com 22 Nov 2024

Replimune group's chief medical officer sells shares worth $78,111 By...

The shares were sold at a price of $10.78 each, amounting to a total transaction value of $78,111...

Investing.com 20 Nov 2024

Replimune's chief commercial officer sells $56,131 in stock By Investing.com

According to a filing with the Securities and Exchange Commission, Sarchi sold 5,207 shares at a...

Investing.com 20 Nov 2024

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings

Overview of the Recent Transaction On September 30, 2024, Morgan Stanley executed a significant t...

GuruFocus.com · via Yahoo Finance 8 Oct 2024

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

Shares of Replimune Group, Inc. (REPL) have gained 16.4% over the past four weeks to close the la...

Zacks via Yahoo Finance 11 Mar 2024

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

Replimune Group, Inc. (REPL) could be a solid choice for investors given its recent upgrade to a ...

Zacks via Yahoo Finance 8 Mar 2024

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move...

Shares of Replimune Group, Inc. (REPL) have gained 0.8% over the past four weeks to close the las...

Zacks via Yahoo Finance 23 Feb 2024

Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway

<img src=https://s.yimg.com/ny/api/res/1.2/GFFacjMQE5JFxUpwjOKI8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyM...

GuruFocus.com via Yahoo Finance 8 Feb 2024